Viatris launches tender for Pacira BioSciences through Peach Purchaser Sub

Viatris commenced a tender offer for Pacira BioSciences through its wholly owned subsidiary Peach Purchaser Sub Inc. The move marks Viatris's entry into the specialty pain management franchise, specifically targeting Pacira's EXPAREL platform—a liposomal bupivacaine generating approximately $470 million in annual revenue. The tender structure signals board approval and avoids the uncertainty of a negotiated merger vote.

Pacira operates in the non-opioid post-surgical pain space, a category that has seen hospital formulary momentum since 2019 as surgical centers rotate away from opioid protocols. EXPAREL competes against standard bupivacaine and Heron Therapeutics' discontinued HTX-011, leaving Pacira with effective category dominance in hospital orthopedic and soft tissue procedures. Viatris, which formed from the 2020 merger of Mylan and Pfizer's Upjohn unit, has largely focused on complex generics and biosimilars across 165 markets. The company reported $16.1 billion in 2023 revenue but has faced margin compression in its legacy oral solid dose portfolio. Pacira's gross margin profile—approximately 81% in recent quarters—offers a structural improvement to Viatris's blended economics.

The tender bypasses a negotiated merger timeline and removes shareholder vote risk for Viatris. Pacira's board recommendation, if secured, accelerates the likely close into Q2 2025. The subsidiary structure—Peach Purchaser Sub—allows Viatris to isolate the transaction's balance sheet treatment and potentially preserve net operating loss carryforwards at the Pacira entity level. Worth noting: Pacira's $1.8 billion market capitalization prior to the announcement represented a 3.8x revenue multiple, below the specialty pharma peer median of 4.7x. If Viatris is offering a 20-25% premium, the implied valuation lands near $2.2-2.3 billion, or roughly 4.7-4.9x trailing revenue—clean sector parity.

The combination gives Viatris a hospital channel asset with embedded formulary relationships, a category that complements its ambulatory generics footprint but does not overlap. Hospital systems have increasingly separated pain management procurement from traditional pharmacy budgets, creating a purchasing dynamic that favors dedicated sales teams. Pacira has 240 hospital-focused representatives; Viatris operates a 3,000-person commercial organization globally. The integration playbook likely involves folding Pacira's U.S. hospital team into a standalone business unit while using Viatris's international infrastructure to explore ex-U.S. regulatory filings for EXPAREL in Canada, EU5, and Australia—markets where liposomal bupivacaine has not yet secured reimbursement.

Operators should monitor the tender offer price when disclosed, the minimum tender condition—likely 50.1% or a majority-of-minority threshold—and any competing interest from private equity sponsors with prior hospital product exposure. SFOs with generics exposure through Viatris debt or equity should assess whether the deal is funded with balance sheet cash, new term debt, or a combination. Pacira's shareholder base includes 12% institutional concentration in Deerfield Management and RA Capital; those positions will anchor the tender response. The HSR filing will clarify timing; most specialty pharma tenders clear within 35-45 days absent FTC second requests.

Viatris has $2.1 billion in cash and $19.4 billion in net debt as of Q3 2024. The acquisition, if priced near $2.3 billion, would likely require a $1.5 billion term loan B and use of existing revolver capacity.